Xiaodong Li, Xia Chen, Xuewei Qin, Dandan Wu, Yi Yang, Zhilin Li
Department of Ophthalmology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China.
J Ophthalmol. 2025 May 6;2025:8891531. doi: 10.1155/joph/8891531. eCollection 2025.
A bibliometric analysis was performed in the domain of ranibizumab and age-related macular degeneration (AMD) to delineate current trends in international research dynamics and to provide a visual representation of research hotspots and challenges associated with ophthalmic drugs over the past 15 years. This study also evaluates the sustainability of ranibizumab therapy through reduced injection burden, cost-effectiveness compared to alternative treatments, and long-term outcomes that minimize healthcare resource utilization. In this cross-sectional study, bibliometrics analyzed data retrieved and extracted from the Web of Science Core Collection (WOSCC) database to analyze the evolution and thematic trends in the delivery of studies from January 1, 2008, to September 2, 2023, for ranibizumab and AMD studies. A total of 2691 articles on the field were assessed for specific characteristics such as the year of publication, journal, author, institution, country/region, citation, and keywords. Co-authorship analysis, co-occurrence analysis, co-citation analysis, and network visualization were constructed using VOSviewer. Some important subtopics identified by bibliometric characterization were further discussed and reviewed. From 2008 to 2023, the cumulative number of articles published globally increased from 1 to 2,691, with the highest number of articles published in 2020 (255 papers). RETINA THE JOURNAL OF RETINAL AND VITREOUS DISEASES published the most manuscripts (285 papers) and was cited (6496 citations), followed by OPHTHALMOLOGY (193 papers) and GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (163 papers). OPHTHALMOLOGY was the most cited (20,865 citations), with the United States (786 papers, 38,014 citations), Univ Sydney (98 papers, 5245 citations), and Kim, Jong Woo (56 papers, 550 citations) being the most productive and influential institutions, countries, and authors, respectively. Five clusters were formed by summarizing the top 100 keywords, which marked the emerging frontier of ranibizumab and AMD-related research. Further discussion of the five clusters of research is to assist the researcher in determining the scope of the research topic and planning the direction of the research. Over the past two decades, there has been a notable increase in the number of publications and citations pertaining to ranibizumab and AMD across various countries, institutions, and authors. This study elucidates current trends, global collaboration patterns, foundational knowledge, research hotspots, and developmental trajectories within the realm of ranibizumab-related AMD research. Key advancements in AMD treatment with ranibizumab over the last 15 years have centered on less frequent injection schedules, extended drug efficacy, and enhanced safety profiles.
我们对雷珠单抗和年龄相关性黄斑变性（AMD）领域进行了文献计量分析，以描绘国际研究动态的当前趋势，并直观呈现过去15年与眼科药物相关的研究热点和挑战。本研究还通过减轻注射负担、与替代治疗相比的成本效益以及使医疗资源利用最小化的长期结果来评估雷珠单抗治疗的可持续性。在这项横断面研究中，文献计量学分析了从科学引文索引核心合集（WOSCC）数据库检索和提取的数据，以分析2008年1月1日至2023年9月2日期间雷珠单抗和AMD研究的发表演变及主题趋势。总共评估了该领域的2691篇文章的具体特征，如发表年份、期刊、作者、机构、国家/地区、引用情况和关键词。使用VOSviewer构建了共同作者分析、共现分析、共被引分析和网络可视化。通过文献计量特征识别出的一些重要子主题得到了进一步讨论和综述。从2008年到2023年，全球发表的文章累计数量从1篇增加到2691篇，2020年发表的文章数量最多（255篇）。《视网膜与玻璃体疾病杂志》发表的手稿最多（285篇）且被引用次数最多（6496次），其次是《眼科学》（193篇）和《格拉夫斯临床与实验眼科学文献》（163篇）。《眼科学》被引用次数最多（20865次），美国（786篇文章，38014次引用）、悉尼大学（98篇文章，5245次引用）和Kim, Jong Woo（56篇文章，550次引用）分别是产出最多且最具影响力的机构、国家和作者。通过总结前100个关键词形成了五个聚类，标志着雷珠单抗和AMD相关研究的新兴前沿。对这五个研究聚类的进一步讨论有助于研究人员确定研究主题的范围并规划研究方向。在过去二十年中，各国、各机构和各作者发表的与雷珠单抗和AMD相关的出版物和引用次数显著增加。本研究阐明了雷珠单抗相关AMD研究领域的当前趋势、全球合作模式、基础知识、研究热点和发展轨迹。过去15年中雷珠单抗治疗AMD的关键进展集中在减少注射频率、延长药物疗效和提高安全性方面。
